RT期刊文章SR电子T1剂量反应relationship of inhaled budesonide in adult asthma: a meta-analysis JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP 552 OP 558 DO 10.1183/09031936.04.00076604 VO 23 IS 4 A1 Masoli, M. A1 Holt, S. A1 Weatherall, M. A1 Beasley, R. YR 2004 UL //www.qdcxjkg.com/content/23/4/552.abstract AB The aim of this study was to examine the dose-response relationship of inhaled budesonide in adolescents and adults with asthma. A meta-analysis was carried out on placebo-controlled, randomised clinical trials, presenting data on at least one outcome measure of asthma and using at least two doses of budesonide, delivered by turbuhaler or metered-dose inhaler+spacer twice daily. A total of six studies of 1,435 adolescents and adults, with mild to moderately severe asthma, met the inclusion criteria for the meta-analysis. A negative exponential model indicated that 80% of the benefit at 1,600 µg·day−1 was achieved at doses of ∼200–400 µg·day−1 and 90% by 300–600 µg·day−1. Meta-regression with a quadratic term in dose showed that the maximum effect was obtained with doses of ∼1,000 µg·day−1. In conclusion, the available published data indicate that, in adolescents and adults with mild to moderate asthma, most of the therapeutic benefit of budesonide delivered by turbuhaler or metered-dose inhaler+spacer is achieved with a dose of ∼400 µg·day−1 and the maximum effect is achieved at ∼1,000 µg·day−1. This conclusion is qualified by the recognition that there is considerable individual variability in the response to inhaled corticosteroids and that the subjects included in this meta-analysis had predominantly mild to moderate asthma.